- Home
- EBS
as of 01-23-2026 3:41pm EST
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 663.3M | IPO Year: | 2006 |
| Target Price: | $15.00 | AVG Volume (30 days): | 968.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.02 - $14.06 | Next Earning Date: | 03-02-2026 |
| Revenue: | $788,900,000 | Revenue Growth: | -29.91% |
| Revenue Growth (this year): | -21.67% | Revenue Growth (next year): | 15.21% |
AI-Powered EBS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Emergent Biosolutions Inc. (EBS)
Director
Avg Cost/Share
$12.00
Shares
21,984
Total Value
$263,077.09
Owned After
98,417
Director
Avg Cost/Share
$10.54
Shares
17,801
Total Value
$187,622.54
Owned After
119,858
SEC Form 4
Director
Avg Cost/Share
$10.00
Shares
8,552
Total Value
$85,520.00
Owned After
88,980
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Richard Ronald | EBS | Director | Dec 5, 2025 | Sell | $12.00 | 21,984 | $263,077.09 | 98,417 | |
| DeGolyer Donald W | EBS | Director | Nov 10, 2025 | Sell | $10.54 | 17,801 | $187,622.54 | 119,858 | |
| Dayal Sujata Tyagi | EBS | Director | Nov 7, 2025 | Sell | $10.00 | 8,552 | $85,520.00 | 88,980 |
Compare EBS vs Leading Stocks
See how EBS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EBS Emergent Biosolutions Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.